Divi's Laboratories Stock Price

DIVISLAB Community Fair Values

• AN

  

  AnalystHighTarget

  Consensus Narrative from 29 Analysts

  Aging Populations And Rising Spending Will Secure Resilient API Manufacturing

  Key Takeaways Expanding capacity, advanced technology adoption, and unique supply capabilities position Divi's as a key innovation partner and supply anchor for global pharma, driving durable margin expansion. Strong long-term client relationships and diversification in high-growth markets ensure compounding revenue growth, pricing power, and sustainable competitive advantages.

  ₹7.90k

  FV

  16.7% undervalued intrinsic discount

  22.31%

  Revenue growth p.a.

  0users have liked this narrative

  0users have commented on this narrative

  0users have followed this narrative

  5 days ago author updated this narrative
• AN

  

  AnalystConsensusTarget

  Consensus Narrative from 29 Analysts

  The Kakinada Phase I Expansion Will Increase Future Manufacturing Capabilities And Efficiency

  Key Takeaways Expansion at Kakinada and backward integration efforts are expected to enhance revenue and net margins through increased manufacturing capabilities and operational efficiency. Growth in the nutraceutical division and custom synthesis business, along with easing price pressures, could stabilize and boost future revenue.

  ₹6.46k

  FV

  1.9% overvalued intrinsic discount

  17.06%

  Revenue growth p.a.

  1users have liked this narrative

  0users have commented on this narrative

  11users have followed this narrative

  5 days ago author updated this narrative
• AN

  

  AnalystLowTarget

  Consensus Narrative from 29 Analysts

  Global Regulations And Trade Tensions Will Hamper Future Prospects

  Key Takeaways Increased compliance costs and shifting industry trends threaten margins and growth, as evolving pharma demands move away from Divi's core small molecule focus. Heavy reliance on limited products and major overseas customers exposes Divi's to revenue instability, margin pressures, and risks from geopolitical disruptions.

  ₹4.63k

  FV

  42.2% overvalued intrinsic discount

  14.49%

  Revenue growth p.a.

  0users have liked this narrative

  0users have commented on this narrative

  0users have followed this narrative

  5 days ago author updated this narrative